The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.
Study Type
OBSERVATIONAL
Enrollment
958
As an induction treatment for kidney transplantation
As an induction treatment for kidney transplantation
The First Affiliated Hospital of Sun Yat-sen University.
Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhejiang University
Hangzhou, China
Changhai Hospital affiliated to Naval Military Medical University
Shanghai, China
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Acute rejection (AR)
The clinical diagnosis of AR is based on a significant increase in serum creatinine and the exclusion of other causes. The diagnosis of biopsy-confirmed AR is based on relevant histological changes.
Time frame: From baseline, kidney transplantation to data collection completion (June 30, 2023)
Cytomegalovirus (CMV) viremia
The serum CMV is greater than 500 copies/ml
Time frame: From baseline, kidney transplantation to data collection completion (June 30, 2023)
Pneumonia
Any pneumonia that showed the presence of lesion and required hospitalization
Time frame: From baseline, kidney transplantation to data collection completion (June 30, 2023)
Renal graft survival
The estimated glomerular filtration rate (eGFR) of patient is \>15 ml/min/1.73m2
Time frame: From baseline, kidney transplantation to data collection completion (June 30, 2023)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.